002262 恩华药业
已收盘 02-04 15:00:00
资讯
新帖
简况
恩华药业公布国际专利申请:“作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途”
证券之星 · 01-30
恩华药业公布国际专利申请:“作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途”
恩华药业公布国际专利申请:“取代的氮杂环丁烷衍生物、其制备方法及其医药用途”
证券之星 · 01-29
恩华药业公布国际专利申请:“取代的氮杂环丁烷衍生物、其制备方法及其医药用途”
股市必读:恩华药业(002262)1月27日董秘有最新回复
证券之星 · 01-28
股市必读:恩华药业(002262)1月27日董秘有最新回复
恩华药业:公司的产品力月西目前没有获得欧盟上市许可
证券之星 · 01-27
恩华药业:公司的产品力月西目前没有获得欧盟上市许可
恩华药业(002262)披露获得《药品注册证书》公告,1月22日股价下跌1.03%
证券之星 · 01-22
恩华药业(002262)披露获得《药品注册证书》公告,1月22日股价下跌1.03%
恩华药业(002262.SZ)取得右酮洛芬氨丁三醇注射液药品注册证书
智通财经 · 01-22
恩华药业(002262.SZ)取得右酮洛芬氨丁三醇注射液药品注册证书
股市必读:恩华药业(002262)1月19日董秘有最新回复
证券之星 · 01-20
股市必读:恩华药业(002262)1月19日董秘有最新回复
恩华药业:科学合理统筹资金提高分红
证券之星 · 01-19
恩华药业:科学合理统筹资金提高分红
恩华药业:麻醉药品市场占有率综合排名靠前
证券之星 · 01-13
恩华药业:麻醉药品市场占有率综合排名靠前
股市必读:恩华药业(002262)1月12日董秘有最新回复
证券之星 · 01-13
股市必读:恩华药业(002262)1月12日董秘有最新回复
恩华药业:NHL35700预计2026年进入三期临床
证券之星 · 01-12
恩华药业:NHL35700预计2026年进入三期临床
恩华药业最新公告:全资子公司与绿叶制药及其子公司签署产品独家商业合作协议
证券之星 · 2025-12-24
恩华药业最新公告:全资子公司与绿叶制药及其子公司签署产品独家商业合作协议
恩华药业(002262)披露取消监事会并修订公司章程公告,12月22日股价下跌0.66%
证券之星 · 2025-12-22
恩华药业(002262)披露取消监事会并修订公司章程公告,12月22日股价下跌0.66%
恩华药业(002262)披露补选1名独立董事公告,12月03日股价上涨0.74%
证券之星 · 2025-12-03
恩华药业(002262)披露补选1名独立董事公告,12月03日股价上涨0.74%
股市必读:恩华药业(002262)11月18日董秘有最新回复
证券之星 · 2025-11-19
股市必读:恩华药业(002262)11月18日董秘有最新回复
股市必读:恩华药业(002262)11月4日董秘有最新回复
证券之星 · 2025-11-05
股市必读:恩华药业(002262)11月4日董秘有最新回复
股市必读:恩华药业(002262)股东户数3.74万户,较上期减少14.2%
证券之星 · 2025-10-27
股市必读:恩华药业(002262)股东户数3.74万户,较上期减少14.2%
恩华药业(002262)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 2025-10-26
恩华药业(002262)2025年三季报简析:营收净利润同比双双增长,盈利能力上升
恩华药业(002262)9月30日股东户数3.74万户,较上期减少14.2%
证券之星 · 2025-10-24
恩华药业(002262)9月30日股东户数3.74万户,较上期减少14.2%
恩华药业(002262.SZ)发布前三季度业绩,归母净利润11.06亿元,同比增长8.42%
智通财经 · 2025-10-24
恩华药业(002262.SZ)发布前三季度业绩,归母净利润11.06亿元,同比增长8.42%
加载更多
公司概况
公司名称:
江苏恩华药业股份有限公司
所属行业:
医药制造业
上市日期:
2008-07-23
主营业务:
江苏恩华药业股份有限公司的主营业务是医药生产、研发和销售。公司的主要产品是力月西、福尔利、芬特、阿纷尼、恩利泽、欧立罗、泊得乐、必和、碳酸锂缓释片、维必朗、阿普唑仑片、恩卓欣、利鲁唑片。报告期内,公司荣获“2025中国药品研发综合实力前50强”荣誉,恩元医学检验实验室获得上海市创新型中小企业荣誉证书;恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。
发行价格:
5.68
{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":23.3,"timestamp":1770188610000,"preClose":22.82,"halted":0,"volume":14592129,"delay":0,"changeRate":0.021,"floatShares":884000000,"shares":1016000000,"eps":1.2104,"marketStatus":"已收盘","change":0.48,"latestTime":"02-04 15:00:00","open":22.8,"high":23.4,"low":22.76,"amount":337000000,"amplitude":0.028,"askPrice":23.31,"askSize":101,"bidPrice":23.3,"bidSize":115,"shortable":0,"etf":0,"ttmEps":1.2104,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770255000000},"marketStatusCode":5,"adr":0,"adjPreClose":22.82,"symbolType":"stock","openAndCloseTimeList":[[1770168600000,1770175800000],[1770181200000,1770188400000]],"highLimit":25.1,"lowLimit":20.54,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1015786583,"isCdr":false,"pbRate":2.86,"roa":"--","peRate":19.249835,"roe":"14.31%","epsLYR":1.13,"committee":0.264874,"marketValue":23668000000,"turnoverRate":0.0165,"status":0,"floatMarketCap":20595000000},"requestUrl":"/m/hq/s/002262","defaultTab":"news","newsList":[{"id":"2607052643","title":"恩华药业公布国际专利申请:“作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607052643","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607052643?lang=zh_cn&edition=full","pubTime":"2026-01-30 06:24","pubTimestamp":1769725455,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示恩华药业(002262)公布了一项国际专利申请,专利名为“作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途”,专利申请号为PCT/CN2025/109166,国际公布日为2026年1月22日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来恩华药业已公布的国际专利申请2个,较去年同期增加了100%。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了3.36亿元,同比增11.36%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000004667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0239","002262","BK0188","LU1064131003.USD","BK0070"],"gpt_icon":0},{"id":"2607725357","title":"恩华药业公布国际专利申请:“取代的氮杂环丁烷衍生物、其制备方法及其医药用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2607725357","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607725357?lang=zh_cn&edition=full","pubTime":"2026-01-29 05:48","pubTimestamp":1769636911,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示恩华药业(002262)公布了一项国际专利申请,专利名为“取代的氮杂环丁烷衍生物、其制备方法及其医药用途”,专利申请号为PCT/CN2025/108807,国际公布日为2026年1月22日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来恩华药业已公布的国际专利申请2个,较去年同期增加了100%。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了3.36亿元,同比增11.36%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900003394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1161","BK0239","09939","BK1574","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK1515","159938","002262","BK0070"],"gpt_icon":0},{"id":"2606734726","title":"股市必读:恩华药业(002262)1月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606734726?lang=zh_cn&edition=full","pubTime":"2026-01-28 02:27","pubTimestamp":1769538431,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘,恩华药业报收于23.9元,下跌1.2%,换手率1.32%,成交量11.65万手,成交额2.78亿元。董秘最新回复投资者: 你好,请问今年最新十大股东有哪些?公司股东户数等信息在公司定期报告中披露并逐期进行更新,敬请您关注公司定期报告。在欧洲是如何布局的呢董秘: 您好!公司的产品力月西目前没有获得欧盟上市许可。当日关注点来自交易信息汇总:1月27日主力资金净流入633.62万元,显示主力对个股短期态度偏积极。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800001420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0070","BK0239","LU2148510915.USD","LU1064130708.USD","BK0188","002262"],"gpt_icon":0},{"id":"2606207978","title":"恩华药业:公司的产品力月西目前没有获得欧盟上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2606207978","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606207978?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:39","pubTimestamp":1769506750,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)01月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,人福医药力月西在欧洲取得了上市许可,作为公司主要产品,公司的力月西是否取得了欧洲的上市许可?在欧洲是如何布局的呢恩华药业回复:您好!公司的产品力月西目前没有获得欧盟上市许可。公司会按照战略规划有步骤地进行相关产品的国际化。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700030039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","FSXEmain","FESXmain","LU2148510915.USD","LU1064130708.USD","BK0239","002262","BK0188","BK0070"],"gpt_icon":0},{"id":"2605497301","title":"恩华药业(002262)披露获得《药品注册证书》公告,1月22日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605497301","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605497301?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:24","pubTimestamp":1769091863,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘,恩华药业报收于24.01元,较前一交易日下跌1.03%,最新总市值为243.89亿元。该股当日开盘24.28元,最高24.39元,最低23.87元,成交额达3.41亿元,换手率为1.6%。公司近日发布公告称,江苏恩华药业股份有限公司近日获得国家药品监督管理局核准签发的右酮洛芬氨丁三醇注射液《药品注册证书》。目前该品种在国内仅有南京正科医药获批。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200040818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0239","002262","BK0070","LU1064131003.USD","BK0188","LU1064130708.USD"],"gpt_icon":0},{"id":"2605463637","title":"恩华药业(002262.SZ)取得右酮洛芬氨丁三醇注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2605463637","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605463637?lang=zh_cn&edition=full","pubTime":"2026-01-22 15:48","pubTimestamp":1769068087,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恩华药业(002262.SZ)公告,公司近日获得国家药品监督管理局核准签发的化学药品右酮洛芬氨丁三醇注射液的《药品注册证书》。右酮洛芬氨丁三醇注射液是一种非甾体抗炎镇痛药,是COX-1和COX-2活性的抑制剂,作为阿片类镇痛药的辅助,用于成人不适合口服给药的急性中度至重度术后疼痛。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恩华药业(002262.SZ)取得右酮洛芬氨丁三醇注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262","BK0070","LU1064131003.USD","LU2148510915.USD","BK0188","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2604137579","title":"股市必读:恩华药业(002262)1月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2604137579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604137579?lang=zh_cn&edition=full","pubTime":"2026-01-20 01:08","pubTimestamp":1768842491,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘,恩华药业报收于24.1元,下跌0.95%,换手率1.55%,成交量13.68万手,成交额3.31亿元。当日关注点来自交易信息汇总:1月19日主力资金净流入2356.09万元,显示主力对恩华药业的积极介入。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000000509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002262","BK0188","BK0239","LU2148510915.USD","BK0070","LU1064130708.USD"],"gpt_icon":0},{"id":"2604903793","title":"恩华药业:科学合理统筹资金提高分红","url":"https://stock-news.laohu8.com/highlight/detail?id=2604903793","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604903793?lang=zh_cn&edition=full","pubTime":"2026-01-19 09:12","pubTimestamp":1768785130,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)01月19日在投资者关系平台上答复投资者关心的问题。投资者提问:公司手上拿着这么多现金,每股未分配利润这么厚,业绩这么优秀,又没有重大项目需投资,而每年分红实在太过小气,今年能不能大气点?恩华药业回复:感谢您对公司的关注和支持!公司非常注重投资者回报,历年来持续进行现金分红。未来,公司会在保障生产经营活动高质量可持续发展的前提下,科学合理地统筹安排资金运用,不断提高分红金额。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900002417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","LU2148510915.USD","002262","LU1064131003.USD","BK0239","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2603681989","title":"恩华药业:麻醉药品市场占有率综合排名靠前","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681989","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603681989?lang=zh_cn&edition=full","pubTime":"2026-01-13 20:51","pubTimestamp":1768308706,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业01月12日在投资者关系平台上答复投资者关心的问题。公司麻醉药品的市场占有率综合排名较为靠前,部分品种的市场占有率较高。公司对于AI应用于制药领域特别重视,已经在投入资源进行探索实践。公司合作建设的江苏省中枢神经药物研究重点实验室目前未在脑机接口领域开展研究,但会持续予以关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300039744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002262","BK0070"],"gpt_icon":0},{"id":"2603547239","title":"股市必读:恩华药业(002262)1月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2603547239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603547239?lang=zh_cn&edition=full","pubTime":"2026-01-13 01:30","pubTimestamp":1768239031,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘,恩华药业报收于24.48元,下跌0.53%,换手率1.61%,成交量14.21万手,成交额3.49亿元。董秘: 答:NHL35700正在与CDE沟通三期临床方案,预计2026年会进入三期临床。当日关注点来自交易信息汇总:1月12日主力资金净流出1991.04万元,散户资金净流入1693.34万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300001367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","LU2148510915.USD","BK0070","LU1064131003.USD","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2602929135","title":"恩华药业:NHL35700预计2026年进入三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2602929135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602929135?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205723,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问:请问 NHL35700二期数据如何, 什么时候开始三期试验?恩华药业回复:答:NHL35700正在与CDE沟通三期临床方案,预计2026年会进入三期临床。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200017435.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002262","BK0070","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2593466471","title":"恩华药业最新公告:全资子公司与绿叶制药及其子公司签署产品独家商业合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2593466471","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593466471?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:39","pubTimestamp":1766576389,"startTime":"0","endTime":"0","summary":"恩华药业公告称,公司全资子公司恩华和信与绿叶制药及其子公司绿叶嘉奥达成产品《独家商业合作协议》,恩华和信将获得绿叶制药的注射用利培酮微球、棕榈酸帕利哌酮注射液及绿叶嘉奥的棕榈酸帕利哌酮注射液共三款抗精神病药长效针剂产品在中国大陆地区开展推广、销售及其他商业化活动的独家权益。合作期限自《协议》生效日起至2035年12月31日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400034413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1606","BK0239","02186","002262","BK0070","BK1583","LU1064130708.USD","LU1064131003.USD","BK1191","LU2148510915.USD","BK0188"],"gpt_icon":0},{"id":"2593852544","title":"恩华药业(002262)披露取消监事会并修订公司章程公告,12月22日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593852544","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593852544?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:53","pubTimestamp":1766397193,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘,恩华药业报收于25.47元,较前一交易日下跌0.66%,最新总市值为258.72亿元。该股当日开盘25.66元,最高25.7元,最低25.32元,成交额达1.85亿元,换手率为0.82%。近日,江苏恩华药业股份有限公司发布2025年第二次临时股东大会决议公告。公告显示,公司于2025年12月19日召开2025年第二次临时股东大会,审议通过了取消监事会、变更经营范围、增加董事会人数、修订《公司章程》并办理工商变更登记的议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0239","002262","BK0188","LU1064131003.USD","BK0070"],"gpt_icon":0},{"id":"2588014824","title":"恩华药业(002262)披露补选1名独立董事公告,12月03日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014824","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014824?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:17","pubTimestamp":1764753465,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘,恩华药业报收于24.45元,较前一交易日上涨0.74%,最新总市值为248.36亿元。近日,江苏恩华药业股份有限公司发布公告称,公司于2025年12月3日召开第七届董事会第五次会议,审议通过补选1名独立董事的议案。本次补选后,公司独立董事人数将由3人增至4人,董事会人数增至10人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300026591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0070","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","BK0188","BK0239"],"gpt_icon":0},{"id":"2584950293","title":"股市必读:恩华药业(002262)11月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584950293","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584950293?lang=zh_cn&edition=full","pubTime":"2025-11-19 02:55","pubTimestamp":1763492112,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘,恩华药业报收于24.3元,上涨0.33%,换手率0.55%,成交量4.9万手,成交额1.19亿元。董秘最新回复投资者: 您好!请问截至10月31日公司股东人数是多少,谢谢!根据信息披露相关规则,公司股东户数等相关信息会在公司定期报告中进行披露。当日关注点来自交易信息汇总:11月18日主力资金净流出1022.53万元,显示主力短期减持动向。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111900001248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","LU1064131003.USD","002262","LU2148510915.USD","LU1064130708.USD","BK0239"],"gpt_icon":0},{"id":"2581175441","title":"股市必读:恩华药业(002262)11月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2581175441","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581175441?lang=zh_cn&edition=full","pubTime":"2025-11-05 01:07","pubTimestamp":1762276037,"startTime":"0","endTime":"0","summary":"截至2025年11月4日收盘,恩华药业报收于24.17元,下跌1.95%,换手率1.13%,成交量9.97万手,成交额2.42亿元。董秘最新回复投资者: 请问贵公司在国家医药集采政策中中标之后,是否出现盈利空间受限之类的情况?其回款账期由国家集采政策相关规定予以明确。当日关注点来自交易信息汇总:11月4日主力资金净流出3598.87万元,占总成交额14.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500000868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0239","LU1064131003.USD","BK0188","BK0070","LU2148510915.USD","002262"],"gpt_icon":0},{"id":"2578725656","title":"股市必读:恩华药业(002262)股东户数3.74万户,较上期减少14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578725656","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578725656?lang=zh_cn&edition=full","pubTime":"2025-10-27 01:14","pubTimestamp":1761498851,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘,恩华药业报收于25.5元,下跌2.0%,换手率1.22%,成交量10.79万手,成交额2.76亿元。交易信息汇总资金流向10月24日主力资金净流出4021.52万元;游资资金净流入18.16万元;散户资金净流入4003.36万元。股本股东变化股东户数变动截至2025年9月30日,公司股东户数为3.74万户,较6月30日减少6196.0户,减幅为14.2%。户均持股数量由上期的2.33万股增至2.71万股,户均持股市值为73.82万元。会议以3票赞成、0票反对、0票弃权审议通过《2025年第三季度报告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","LU2148510915.USD","BK0070","BK0239","BK0188","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2578102683","title":"恩华药业(002262)2025年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2578102683","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578102683?lang=zh_cn&edition=full","pubTime":"2025-10-26 06:12","pubTimestamp":1761430322,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期恩华药业发布2025年三季报。截至本报告期末,公司营业总收入44.71亿元,同比上升7.85%,归母净利润11.06亿元,同比上升8.42%。按单季度数据看,第三季度营业总收入14.61亿元,同比上升5.7%,第三季度归母净利润4.06亿元,同比上升3.67%。本报告期恩华药业盈利能力上升,毛利率同比增幅3.08%,净利率同比增幅0.74%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"gpt_icon":0},{"id":"2577596794","title":"恩华药业(002262)9月30日股东户数3.74万户,较上期减少14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577596794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577596794?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:12","pubTimestamp":1761297165,"startTime":"0","endTime":"0","summary":"证券之星消息,近日恩华药业披露,截至2025年9月30日公司股东户数为3.74万户,较6月30日减少6196.0户,减幅为14.2%。在化学制药行业个股中,恩华药业股东户数高于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.23万户。从股价来看,2025年6月30日至2025年9月30日,恩华药业区间涨幅为30.9%,在此期间股东户数减少6196.0户,减幅为14.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","002262","BK0188","BK0239","LU2148510915.USD","BK0070","LU1064130708.USD"],"gpt_icon":0},{"id":"2577466593","title":"恩华药业(002262.SZ)发布前三季度业绩,归母净利润11.06亿元,同比增长8.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577466593","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577466593?lang=zh_cn&edition=full","pubTime":"2025-10-24 16:23","pubTimestamp":1761294213,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恩华药业(002262.SZ)发布2025年三季度报告,前三季度,公司实现营业收入44.71亿元,同比增长7.85%。归属于上市公司股东的净利润11.06亿元,同比增长8.42%。归属于上市公司股东的扣除非经常性损益的净利润11.09亿元,同比增长7.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1359329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恩华药业(002262.SZ)发布前三季度业绩,归母净利润11.06亿元,同比增长8.42%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770237992404,"stockEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0423},{"period":"6month","weight":0.01},{"period":"1year","weight":0.0311},{"period":"ytd","weight":-0.0344}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0236},{"period":"6month","weight":0.1285},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0336}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37430人(较上一季度减少14.20%)","perCapita":"23614股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101578万元","survey":" 江苏恩华药业股份有限公司的主营业务是医药生产、研发和销售。公司的主要产品是力月西、福尔利、芬特、阿纷尼、恩利泽、欧立罗、泊得乐、必和、碳酸锂缓释片、维必朗、阿普唑仑片、恩卓欣、利鲁唑片。报告期内,公司荣获“2025中国药品研发综合实力前50强”荣誉,恩元医学检验实验室获得上海市创新型中小企业荣誉证书;恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}